We are pleased to present the recording of a webinar featuring Geert Vanden Bossche, DMV, PhD, independent virologist and vaccine expert, and Peter McCullough, MD, MPH, one of the most prominent and most published experts on COVID-19 outpatient treatment. Their bios can be found below.
Important: we will do a follow up interview with the speakers, in the upcoming weeks. If you have a question in mind, kindly use this form to let us know your question so that will help us prepare the next interview. Thanks.
This segment of the webinar, which is a discussion between the two experts, moderated by Jean-Pierre Kiekens, founder & editor of covexit.com, is presented first, as it outlines important urgent policy recommendations, that are of immediate relevance and should be carefully considered by any individual in a policy making / decision making position.
The analysis by Geert Vanden Bossche has sent some shockwaves around the world in the past days. Is this pandemic kind of ending, thanks to the various measures taken by governments, including large scale vaccination, as many politicians believe, or could we be at the beginning of a major new wave? Geert Vanden Bossche’s analysis suggests we may enter this second scenario, and that many younger people could get sick with COVID-19, in part because of unforeseen consequences of the ongoing health policy interventions. Geert Vanden Bossche suggests to watch very closely the situation in jurisdictions such as Gibraltar, Israel and the UK, to figure out if “immune escape” is actually happening, with the risk of triggering new variants and new waves of infections.
For his part Peter McCullough explains how wrong many jurisdictions have been in denying early outpatient treatment to the population, relying instead on hospitalization after a period of “watchful waiting” in self-quarantine. He reiterates the pathophysiological basis and rationale for early outpatient treatment. He also talks about his own experience with COVID-19, how he overcame the disease with early outpatient treatment, and how he believes he thereby avoided “long covid” symptoms, a topic he comments upon in some detail. There are also comments on early home treatments such as mouthwashes, and the failure of the medical and research complex to design clinical trials with immediate usefulness for medical doctors on the frontline, treating patients on an ambulatory basis.
Most importantly, the two experts share their very top recommendations for handling this pandemic from now on.
Geert Vanden Bossche, DVM, PhD
Geert Vanden Bossche received his DVM from the University of Ghent, Belgium, and his PhD degree in Virology from the University of Hohenheim, Germany. He held adjunct faculty appointments at universities in Belgium and Germany. After his career in Academia, Geert joined several vaccine companies (GSK Biologicals, Novartis Vaccines, Solvay Biologicals) to serve various roles in vaccine R&D as well as in late vaccine development. Geert then moved on to join the Bill & Melinda Gates Foundation’s Global Health Discovery team in Seattle (USA) as Senior Program Officer; he then worked with the Global Alliance for Vaccines and Immunization (GAVI) in Geneva as Senior Ebola Program Manager. At GAVI he tracked efforts to develop an Ebola vaccine. He also represented GAVI in fora with other partners, including WHO, to review progress on the fight against Ebola and to build plans for global pandemic preparedness. Back in 2015, Geert scrutinized and questioned the safety of the Ebola vaccine that was used in ring vaccination trials conducted by WHO in Guinea. His critical scientific analysis and report on the data published by WHO in the Lancet in 2015 was sent to all international health and regulatory authorities involved in the Ebola vaccination program. After working for GAVI, Geert joined the German Center for Infection Research in Cologne as Head of the Vaccine Development Office. He is at present primarily serving as a Biotech/ Vaccine consultant while also conducting his own research on Natural Killer cell-based vaccines.
Peter McCullough, MD, MPH
Peter McCullough is Professor of Medicine, Vice Chief of Internal Medicine at Baylor University Medical Center in Dallas, Texas. After receiving a bachelor’s degree from Baylor University, Dr. McCullough completed his medical degree as an Alpha Omega Alpha graduate from the University of Texas Southwestern Medical School in Dallas. He went on to complete his internal medicine residency at the University of Washington in Seattle, cardiology fellowship including service as Chief Fellow at William Beaumont Hospital, and master’s degree in public health at the University of Michigan. Dr. McCullough is a consultant cardiologist and Vice Chief of Medicine at Baylor University Medical Center in Dallas, TX. He is a Principal Faculty in internal medicine for the Texas A & M University Health Sciences Center. Dr. McCullough is an internationally recognized authority on the role of chronic kidney disease as a cardiovascular risk state with > 1000 publications and > 500 citations in the National Library of Medicine. His works include the “Interface between Renal Disease and Cardiovascular Illness” in Braunwald’s Heart Disease Textbook. Dr. McCullough is a recipient of the Simon Dack Award from the American College of Cardiology and the International Vicenza Award in Critical Care Nephrology for his scholarship and research. Dr. McCullough is a founder and current president of the Cardiorenal Society of America, an organization dedicated to bringing cardiologists and nephrologists together to work on the emerging problem of cardiorenal syndromes. His works have appeared in the New England Journal of Medicine, Journal of the American Medical Association, Lancet and other top-tier journals worldwide. He is the co-editor of Reviews in Cardiovascular Medicine, and associate editor of the American Journal of Cardiology and Cardiorenal Medicine. He serves on the editorial boards of multiple specialty journals. Dr. McCullough has made presentations on the advancement of medicine across the world and has been an invited lecturer at the New York Academy of Sciences, the National Institutes of Health, U.S. Food and Drug Administration (FDA), European Medicines Agency, and the U.S. Congressional Oversight Panel.